Analysts Conflicted on These Healthcare Names: Haemonetics (HAE), Caladrius Biosciences (CLBS) and Adicet Bio (ACET)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Haemonetics (HAE – Research Report), Caladrius Biosciences (CLBS – Research Report) and Adicet Bio (ACET – Research Report).

Haemonetics (HAE)

Needham analyst Michael Matson maintained a Hold rating on Haemonetics today. The company’s shares closed last Wednesday at $73.46, close to its 52-week high of $75.34.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.8% and a 48.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Haemonetics has an analyst consensus of Moderate Buy, with a price target consensus of $74.80.

See Insiders’ Hot Stocks on TipRanks >>

Caladrius Biosciences (CLBS)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Caladrius Biosciences today and set a price target of $6.00. The company’s shares closed last Wednesday at $0.51, close to its 52-week low of $0.40.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.6% and a 28.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics.

The the analyst consensus on Caladrius Biosciences is currently a Moderate Buy rating.

Adicet Bio (ACET)

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Adicet Bio, with a price target of $25.00. The company’s shares closed last Wednesday at $17.75.

According to TipRanks.com, Roy is a 4-star analyst with an average return of 4.5% and a 31.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Adicet Bio is a Strong Buy with an average price target of $28.50, which is a 65.7% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HAE:

• JMP Securities Keeps Their Buy Rating on PolyPid (PYPD)
• Rackspace Technology Enables Konesh Mission Critical Operation for Certified Accounting and Tax Management
• TOMI Advances SteraMist Disinfection in the Food Safety Industry
• Zynerba Pharmaceuticals (ZYNE) Gets a Hold from Needham
• HII Marks Milestone in Virginia-Class Submarine Massachusetts (SSN 798) Construction